FDG PET/CT用于评估肺癌患者免疫治疗反应
本文综述FDG PET/CT在肺癌免疫检查点抑制剂(ICI)治疗反应评估中的应用。ICI可导致假性进展、超进展和分离反应等非典型反应模式,传统RECIST 1.1标准存在局限。FDG PET/CT的标准化摄取值预测结局有限,而肿瘤代谢体积、总病灶糖酵解、肠道微生物组代谢活性及影像组学等新指标,以及靶向PD-L1等免疫检查点的PET示踪剂,在预测ICI反应方面显示出前景;影像专家还需识别免疫相关不良事件(如肺炎、结肠炎)的代谢模式。
要点
- ICI治疗可呈现假性进展、超进展和分离反应等非典型模式,RECIST 1.1评估受限。
- 标准化摄取值预测ICI结局有限,肿瘤代谢体积、总病灶糖酵解、影像组学等新指标有前景。
- 影像专家需识别ICI相关肺炎、结肠炎等免疫相关不良事件的代谢模式。
核心结论
- FDG PET/CT有潜力成为评估ICI治疗反应的有用标志物。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- ICI单药或联合治疗是无驱动基因突变的晚期肺癌患者的标准治疗。
- ICI治疗患者可出现假性进展、超进展和分离反应等非典型反应模式。
- 标准化摄取值预测ICI治疗结局的能力有限。
- 肿瘤代谢体积、总病灶糖酵解、肠道微生物组代谢活性及影像组学显示作为核医学ICI生物标志物的前景。
- 靶向PD-L1等免疫检查点的PET示踪剂在预测ICI反应方面也显示出有前景的结果。
关键数值与推荐
- FDG PET/CT现已纳入非小细胞肺癌患者的常规分期。
- 尽管ICI治疗反应率更高,但可导致肺炎或结肠炎等免疫相关不良事件。
临床怎么用
- 原文未据此给出推荐,仅指出影像专家识别ICI相关毒性代谢模式极为重要。
局限性
- 标准化摄取值在预测ICI治疗结局方面有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last decade, several strategies have revolutionized the clinical management of patients with lung cancer, including immunotherapy. Indeed, immune checkpoint inhibitors (ICI) monotherapy or in combination represent the standard-of-care for patients with advanced disease with no actionable mutation. Due to the unique action of ICI to potentiate the immune system, conventional response assessment criteria in medical imaging, such as RECIST 1.1, have limitations. Unlike chemotherapy, patients treated with ICI can present atypical response patterns including pseudoprogression, hyper-progression, and dissociated response. Therefore, the creation and implementation of novel standardized response criteria that consider these distinct response patterns is of critical importance. In parallel, FDG PET/CT is now part of the routine staging for patients with nonsmall cell lung cancer. Moreover, there is an increasing interest in using FDG PET/CT metrics for predicting response to ICI therapy. While standardized uptake values are limited in predicting outcomes, new metrics including tumor metabolic volume, total lesion glycolysis, metabolic activity of the gut microbiome, and radiomics show promise as potential nuclear-medicine ICI biomarkers. Moreover, PET tracers that specifically target immune checkpoints such as PD-L1 also showed promising results in predicting ICI response. Finally, despite achieving higher response rates, ICI therapy leads to the development of immune-related adverse events such as pneumonitis or colitis. Therefore, it is of upmost importance for the imaging specialist to recognize the metabolic patterns associated with these new toxicity profiles. In this paper, we will review how the FDG PET/CT can potentially become a useful marker for the evaluation of ICI response.
引用
- Léger MA, Routy B, Juneau D, et al. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Semin Nucl Med. 2022. PMID: 35636978. doi:10.1053/j.semnuclmed.2022.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。